Morgan Stanley
ODT

Morgan Stanley’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Morgan Stanley’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,017
Closed -$24K – 8392
2021
Q4 		$24K Sell
18,017
-387,882
-96% -$917K ﹤0.01% 7155
2021
Q3 		$1.18M Sell
405,899
-792,311
-66% -$2.63M ﹤0.01% 4946
2021
Q2 		$4.18M Buy
1,198,210
+1,083,562
+945% +$3.72M ﹤0.01% 3972
2021
Q1 		$392K Sell
114,648
-432,719
-79% -$8.18M ﹤0.01% 5293
2020
Q4 		$10.5M Buy
547,367
+545,634
+31,485% +$8.42M ﹤0.01% 2461
2020
Q3 		$23K Sell
1,733
-9,095
-84% -$258K ﹤0.01% 6018
2020
Q2 		$458K Sell
10,828
-57,306
-84% -$1.85M ﹤0.01% 4646
2020
Q1 		$1.88M Sell
68,134
-54,197
-44% -$1.58M ﹤0.01% 3423
2019
Q4 		$3.97M Sell
122,331
-37,113
-23% -$1.15M ﹤0.01% 3446
2019
Q3 		$4.15M Buy
159,444
+58,915
+59% +$1.97M ﹤0.01% 3071
2019
Q2 		$3.69M Sell
100,529
-31,139
-24% -$746K ﹤0.01% 3234
2019
Q1 		$2.91M Buy
131,668
+41,598
+46% +$727K ﹤0.01% 3251
2018
Q4 		$1.27M Buy
90,070
+77,963
+644% +$1.21M ﹤0.01% 4105
2018
Q3 		$235K Sell
12,107
-2,486
-17% -$50.7K ﹤0.01% 5379
2018
Q2 		$322K Sell
14,593
-506
-3% -$11.8K ﹤0.01% 5344
2018
Q1 		$320K Buy
15,099
+11,581
+329% +$273K ﹤0.01% 5248
2017
Q4 		$88K Buy
+3,518
New +$83.1K ﹤0.01% 5675

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Morgan Stanley's ODT Position: Q1 2022 in Review

Morgan Stanley sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 18,017 shares — an estimated $24K sold.

Morgan Stanley first reported a position in ODT in Q4 2017 and held it in 17 quarters. The position peaked at $10.5M in Q4 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Morgan Stanley reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Morgan Stanley sold 18,017 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $24K.
  • Morgan Stanley first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
  • Morgan Stanley's Odonate Therapeutics, Inc. Common Stock position peaked at $10.5M in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Morgan Stanley's 13F filing for Q1 2022, filed 13 May 2022.